• Krka Pharmaceutical Laboratory was established
  • Krka Production Plant was established
  • the first patent was registered
  • Krka re-locates to Ločna where a major part of production still occurs today
  • Establishment of the Development Institute
  • First cosmetic products launched
  • First export ventures


  • Construction of the new plant for manufacturing active ingredients
  • Extension of a new plant for manufacturing tablets and coated tablets
  • Construction of a new plant for producing ointments, syrups and injections
  • Collection and processing of medicinal herbs
  • Expansion to tourist and spa services
  • Presentation of the first Krka Awards


  • registration granted by the American FDA for the manufacture of antibiotics
  • the Dawa Pharmaceutical production plants began operation in Kenya
  • fermentation capacities were increased by 50 %
  • construction of a plant for converting pharmaceutical active ingredients into finished products
  • investment in preservation of clean waters and environment protection
  • construction of the factory in Ljutomer
  • investment in tourist/health-resort facilities


  • construction of a plant producing insulation material
  • building marketing network abroad (establishment of companies and representative offices)
  • accelerated development of Krka’s own generic drugs, and continual cooperation with the leading international pharmaceutical companies
  • ranking in the top Slovene companies and exporters
  • modernisation of fermentation production
  • ensuring a highly qualified professional work force through the project of staff development
  • increased investment in research and development


  • top-place ranking among pharmaceutical companies in Central and Eastern Europe, and penetration into Western European markets
  • investment in research and development activities
  • upgrading the Total Quality Management system
  • restructuring into a joint-stock company


  • completion of the construction of the modern plant Notol for the production of solid dosage at the central Krka location
  • expansion of production-distribution network abroad (new production-distribution plants in Poland, the Russian Federation and in Croatia)
  • a new plant for the production of solid dosage forms in Šentjernej
  • expansion of marketing and sales network
  • Development and Control Centre 2
  • Acquisition of ISO 14001 standard (new quality in environment protection)
  • Implementation of the new SAP information system
  • Acquisition of the foodstuff safety system certificate (HACCP), safety and health at work (OHSAS 18001) and the certificate by the European Agency for Safety and Health at Work (EU-OSHA)
  • Construction of the plant for the production of active pharmaceutical ingredients Synthesis 4


  • Expansion of the marketing and sales network
  • Opening of Sinteza 4 API plant
  • Introduction of no-par value shares (1:10 share split)
  • Acquisition of ISO/IEC 27001 certificate for the information security system
  • Highest national award for quality – the Business Excellence Award of the Republic of Slovenia (PRSPO) for 2007.
  • Opening of the new injection production plant
  • A new business centre for warehousing products, customs operations and marketing activities in Macedonia
  • Entry into a private Chinese pharmaceutical and chemical companies Zhejiang Menova Pharmaceuticals Co., Ltd., Shanghai and Anhua Menova Pharmaceuticals Co., Ltd., Gvande
  • Purchase of German company TAD Pharma GmbH from Cuxhavna and Austrian company Alternova Arzneimittell GmbH from Vienna
  • New chemical development laboratories


  • Opening of a state-of-the-art syrup production plant
  • Opening of a state-of-the-art plant for the production of products with biocidal effect
  • Starting the solar power plant
  • Renovation and enlargement of a high bay warehouse for packaging material
  • Opening of a state-of-the-art solid dosage forms production plant
  • Opening of development and control centre RKC 3
  • Listing of Krka's shares on the Warsaw Stock Exchange
  • Founding the company Farma GRS, d. o. o., together with partners within the pharmaceutical industry development project and building development and research, and production capacities
  • Opening of the Krka-Rus 2 plant in the Russian Federation
  • Opening of the plant for the production of active pharmaceutical ingredients Sinteza 1 in Krško
  • Opening of the largest investment in Krka's history – a plant for the production of solid dosage forms Notol 2 with an annual production capacity of 4.5 billion of finished products
  • Opening of a plant for the new generation lozenges in Ljutomer
  • Strengthening the marketing and sales network comprising 28 subsidiaries and 19 representative offices together with production and distribution companies